New opportunity for innovation capital investment
27.09.2023
Strengthening the efficiency of innovation and increasing innovation performance that
leads to business returns are key issues for the expected competitiveness turnaround in our country. The
latter is linked to how to enhance the role of venture capital in the innovation process, especially in its
early stages. In June 2023, an essential regulation was introduced that significantly affects the
functioning of venture capital: the Parliament decided that business angels and institutional investors
investing in the pre-seed and seed phases can use a convertible instruments. Many hope that the new legal
framework will boost to innovation capital investment. Essentially, investors can provide a loan to an
unlisted company that is less than five years old and has not yet paid dividends, which can be converted
into equity under certain conditions during a capital raise. This can be repeated several times within a
year.
Genomate Health has joined CancerX
03.06.2023
Genomate Health and CancerX have recently joined forces to advance the fight against
cancer by unleashing the power of digital innovation. The aim of this public-private partnership is to unite
multiple stakeholders and innovators to create a future that's free of the burden of cancer. Through this
partnership, Genomate Health and CancerX will work together to develop and implement cutting-edge digital
solutions that empower oncologists to provide more personalized and effective cancer treatments. By
leveraging the latest advancements in artificial intelligence and precision oncology, the partnership will
help oncologists to make better, data-driven decisions about cancer treatment options.
Guidance means accuracy
31.01.2020
A randomized clinical trial was conducted to compare all three known static guided
surgery protocols (pilot, partial, and full) with each other and with freehand surgery in terms of accuracy,
under the same conditions. A total of 207 implants of the same brand and type were placed in 101 partially
edentulous volunteers in need of implantation in the mandible or maxilla or both. All cases were digitally
planned, and the comparison of the planned and actual implant positions was performed using a medical image
analysis software with dedicated algorithms. As for the comparison that this study sought to perform, it can
be said that the static guided approach significantly improves the accuracy of dental implant surgery as
compared to freehand surgery.
Oncompass Medicine won the Digitaleurope competition
04.02.2021
Oncompass Medicine, the predecessor company of Genomate Inc won the Digitaleurope
competition, so this year a Hungarian biotechnology company has become the continent’s most promising
company. With the Future Unicorn Award, they award businesses that are expected to be Europe’s most valuable
technology companies that make the most important technology companies. Oncompass Medicine has developed
a new technology for the selection of targeted therapy for cancer patients. The Real-Time Oncology Treatment
Calculator ranks personalized, targeted therapeutic options in 405 types of cancer in just 20 milliseconds.
Oncompass's results are praised by Ursula von der Leyen
10.02.2022
Ursula von der Leyen, the President of the European Commission, praised the achievements
of Oncompass Medicine. In the summer of 2021, the Hungarian team at Oncompass Medicine made a significant
scientific advancement in the field of precision oncology and cancer treatment. The experts were among the
first to demonstrate the utility of artificial intelligence in the personalized application of targeted
cancer therapies. The scientific results serving as evidence were published in the Precision Oncology
journal. The calculator software developed by the company has already attracted attention at the European
level. During the opening of the conference on European digital development, Ursula von der Leyen
highlighted the work of Oncompass, founded by cancer researcher István Peták.